Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C40H69NO12 |
| Molecular Weight | 755.9754 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 16 / 16 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]2(O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(OC)C(=O)[C@@H](C)C3=C(C)C[C@@](C)(O3)[C@]([H])(O[C@@H]4O[C@H](C)C[C@@H]([C@H]4O)N(C)C(C)C)[C@H]2C
InChI
InChIKey=BELMMAAWNYFCGF-PZXAHSFZSA-N
InChI=1S/C40H69NO12/c1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29/h20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3/t22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-/m1/s1
Mitemcinal (GM-611), an erythromycin-derived prokinetic agent, was developed by Chuga as an agonist of the motilin receptor. Mitemcinal acts by a novel mechanism whereby it stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract. This drug was studied as a potential treatment for gastric motility disorder, as well as reflux esophagitis, non-ulcer dyspepsia, and diabetic gastroparesis. Mitemcinal was involved in phase II clinical trials in Patients with diabetic gastroparesis. Although gastroparetic symptoms improved with both mitemcinal and placebo, the prominent placebo effect was not statistically exceeded by mitemcinal. That is why the development of this drug has stalled. In addition, mitemcinal has been studied in phase II for the treatment of irritable bowel syndrome, but this study was also discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model. | 2007 Aug |
|
| Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin. | 2007 Aug |
|
| Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. | 2007 Oct 15 |
|
| Phase II drugs under clinical investigation for the treatment of chronic constipation. | 2014 Nov |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MITEMCINAL
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
DTXSID00870028
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
CHEMBL2110756
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
300000037001
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
6918267
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
DB06587
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
C166967
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
8171
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
6X5NRJ664L
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
C103741
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY | |||
|
154738-42-8
Created by
admin on Sat Dec 16 17:19:27 UTC 2023 , Edited by admin on Sat Dec 16 17:19:27 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
